Eurosurv. Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 20

[tetano]

• Mario Fontán-Vela[SUP]1,2[/SUP] , Esther Kissling[SUP]3[/SUP] , Nathalie Nicolay[SUP]4[/SUP] , Toon Braeye[SUP]5[/SUP] , Izaak Van Evercooren[SUP]5[/SUP] , Christian Holm Hansen[SUP]6[/SUP] , Hanne-Dorthe Emborg[SUP]6[/SUP] , Massimo Fabiani[SUP]7[/SUP] , Alberto Mateo-Urdiales[SUP]7[/SUP] , Ala'a AlKerwi[SUP]8[/SUP] , Susanne Schmitz[SUP]8[/SUP] , Jesús Castilla[SUP]9,10[/SUP] , Iván Martínez-Baz[SUP]9,10[/SUP] , Brechje de Gier[SUP]11[/SUP] , Susan Hahné[SUP]11[/SUP] , Hinta Meijerink[SUP]12[/SUP] , Jostein Starrfelt[SUP]12[/SUP] , Baltazar Nunes[SUP]13[/SUP] , Constantino Caetano[SUP]13[/SUP] , Tarik Derrough[SUP]4[/SUP] , Anthony Nardone[SUP]3[/SUP] , Susana Monge[SUP]1,14[/SUP] , VEBIS-Lot4 working group[SUP]15[/SUP]

To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.

​https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.1.2300670